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Spred2‑deficiency enhances 
the proliferation of lung epithelial 
cells and alleviates pulmonary 
fibrosis induced by bleomycin
Akina Kawara1, Ryo Mizuta1, Masayoshi Fujisawa1, Toshihiro Ito2, Chunning Li1, 
Kaoru Nakamura1, Cuiming Sun1, Masaki Kuwabara1, Masahiro Kitabatake2, 
Teizo Yoshimura 1 & Akihiro Matsukawa1*
The mitogen‑activated protein kinase (MAPK) pathways are involved in many cellular processes, 
including the development of fibrosis. Here, we examined the role of Sprouty‑related EVH‑1‑domain‑
containing protein (Spred) 2, a negative regulator of the MAPK‑ERK pathway, in the development of 
bleomycin (BLM)‑induced pulmonary fibrosis (PF). Compared to WT mice,  Spred2−/− mice developed 
milder PF with increased proliferation of bronchial epithelial cells.  Spred2−/− lung epithelial cells or 
MLE‑12 cells treated with spred2 siRNA proliferated faster than control cells in vitro.  Spred2−/− and 
WT macrophages produced similar levels of TNFα and MCP‑1 in response to BLM or lipopolysaccharide 
and myeloid cell‑specific deletion of Spred2 in mice had no effect.  Spred2−/− fibroblasts proliferated 
faster and produced similar levels of MCP‑1 compared to WT fibroblasts. Spred2 mRNA was almost 
exclusively detected in bronchial epithelial cells of naïve WT mice and it accumulated in approximately 
50% of cells with a characteristic of Clara cells, 14 days after BLM treatment. These results suggest 
that Spred2 is involved in the regulation of tissue repair after BLM‑induced lung injury and increased 
proliferation of lung bronchial cells in  Spred2−/− mice may contribute to faster tissue repair. Thus, 
Spred2 may present a new therapeutic target for the treatment of PF.
Idiopathic pulmonary fibrosis (IPF) is one of the lung interstitial pneumonias, defined as interstitial fibrosis 
that grows chronically and  progressively1–3. It is generally thought that IPF is a consequence of multiple events 
involving genetic and environmental risk factors, and repetitive microinjuries to ageing alveolar epithelium 
result in activation of alveolar epithelial cells to secrete fibrogenic growth factors, cytokines, and coagulants, 
leading to the recruitment and activation of myofibroblasts. These myofibroblasts deposit increased amounts 
and altered extracellular matrix, with increased biomechanical stiffness, further contributing to myofibroblast 
activation in a positive feedback loop. Since patients with IPF often develop dyspnea, it heavily damages their 
daily life  activities1–3.
Histologically, IPF is characterized by the remodeling of the alveolar architecture. Notably normal alveolar 
epithelial cells and endothelial cells are lost and replaced by fibroblasts, with an appearance of usual interstitial 
pneumonia (UIP)  pattern1,3. The causes of IPF are mostly unknown except for cases, such as drug-induced 
PF; therefore, effective therapies for IPF are lacking and patients are treated just to reduce their  symptoms4. To 
establish new therapies, a number of studies have been conducted using the murine bleomycin (BLM)-induced 
PF model, a commonly used model of human IPF. Bleomycin (BLM) is a chemotherapeutic antibiotic, produced 
by the bacterium “Streptomyces verticillus”5,6. Its primary clinical use is as an antitumor antibiotic for various 
carcinomas and lymphomas. BLM-induced toxicity occurs predominantly in the organs, such as the lung, skin, 
and mucous membranes, due to the lack of the BLM-inactivating enzyme, bleomycin hydrolase in these tissues. 
Pulmonary fibrosis is a well-known side effect of BLM, because the lung expresses very low levels of this enzyme. 
Instillation of BLM to the lung of animals causes pulmonary injury, inflammation, and subsequent  fibrosis7,8.
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Mitogen activated protein kinases (MAPKs), including extracellular signal-regulated kinase (ERK), c-jun 
N-terminal kinase (JNK), and p38 kinase (p38 MAPK), regulate important cellular processes, including gene 
expression, cell proliferation, cell survival and death, and cell  motility9. In general, p38 MAPK and JNK are acti-
vated by environmental stresses and inflammatory cytokines and play important roles in cytokine expression and 
apoptosis, whereas ERK is activated by mitogenic stimuli and stimulates DNA synthesis and cell proliferation and 
protects cells from  apoptosis10. ERK, JNK, and p38 MAPK were all activated in lung tissues from patients with IPF 
compared with normal lung  parenchyma11. Inhibition of ERK with the MEK inhibitor PD98059 reduced the lung 
injury and inflammation after the intratracheal BLM administration in mice. Inhibition of ERK and p38 MAPK 
with PD98059 and SB203580, respectively, remarkably reduced the amiodarone-induced proliferative response of 
human embryonal lung fibroblasts and greatly attenuated α-SMA, vimentin and collagen I protein  production12. 
These previous observations suggested an important role of MAPKs in the development of PF, including IPF.
Sprouty-related EVH1 (enabled/vasodilator-stimulated phosphoprotein homology 1)-domain-containing 
proteins (Spreds) can inhibit Raf activation, resulting in ERK1  inactivation13,14. Spred family proteins, includ-
ing Spred1, Spred2, and Spred3, inhibit the MAPK cascade mediated by fibroblast growth factor receptor and 
epidermal growth factor receptor, by binding to Ras and consequently inhibiting the phosphorylation of  Raf15. 
Particularly, Spred2 is expressed in various tissues, including the  lung16–18. Our previous studies focusing on 
Spred2 demonstrated that Spred2 controls the development of lung inflammatory responses by negatively regulat-
ing the ERK pathway using an acute lung injury (ALI) model induced by lipopolysaccharide (LPS)19,20, leading 
us to the hypothesis that Spred2-deficiency may aggravates the development of PF.
In the present study, we examined the role of Spred2 in BLM-induced PF and demonstrate, for the first time, 
that contrary to our hypothesis Spred2-deficiency abates the development of BLM-induced PF with increased 
proliferation of epithelial cells which may facilitates the repair of injured epithelial cells and reduce subsequent 
fibrosis.
Results
Spred2‑deficiency alleviates BLM‑induced PF. We first examined the lung of naïve WT and  Spred2−/− 
mice (Fig. 1a). Histological examination of lung tissue sections showed that there were no detectable differences 
in the structure or the condition of the lung. Incorporation of BrdU was detected by immunohistochemistry 
(IHC) in a small number of bronchial epithelial cells, including Keratin 5 (Ker5)+ basal cells and Clara cell 10 
kD protein (CC10, also known as Secretoglobin 1a1)+ Clara cells, in the lung of both WT and  Spred2−/− mice 
(Fig. 1b, Supplementary Fig. S1). We also examined the expression of genes expressed by lung epithelial cells 
or mesenchymal cells by qRT-PCR. The expression of Cadherin (Cadh) 1 was slightly increased, whereas the 
expression of Fibronectin 1 (Fn1) and Vimentin (Vim) mRNA was slightly decreased. The expression of Col-
lagen1a (Col1a1) mRNA was similar (Fig. 1c). Thus, Spred2-deficicncy has little effects on the basal structure 
or condition of the lung although minor differences in the expression of some genes were found in the lung of 
 Spred2−/− mice.
To examine a potential role of Spred2 in host responses to tissue injury in the lung, we intratracheally admin-
istered 1.5 mg/kg BLM in WT and  Spred2−/− mice and compared the development of PF. As shown in Fig. 2a, a 
significant level of PF with alveolar destruction, leukocyte recruitment and collagen fiber deposition (stained blue 
by Masson’s trichrome staining) was detected in the lung of WT mice by day 7. The level of PF peaked on day 14 
with increased collagen fiber deposition but PF was largely resolved with only small fibrotic lesions by day 28. In 
contrast to WT mice, the deposition of collagen fibers was milder in  Spred2−/− mice on day 7 and 14 (Fig. 2a,b) 
and PF was almost completely resolved by day 28. As far as leukocyte infiltration, a similar level of neutrophil 
infiltration was detected in the lung of both WT and  Spred2−/− mice on day 7 (Fig. 2c). The levels of MCP-1 in 
the lung of  Spred2−/− mice were significantly lower than in WT mice on day 7 and 14 (Fig. 2d). The expression 
of Fn1 and Vim mRNA was also lower in the lung of  Spred2−/− mice on day 14 (Fig. 2e). When the dose of BLM 
was increased to 3 mg/kg, 8 of 11 WT mice (72.7%) died by day 14 with high levels of PF, whereas only 2 of 9 
 Spred2−/− mice (22.2%) died (Fig. 2f). These results indicated that Spred2-deficiency alleviates the development 
of BLM-induced PF with reduced levels of MCP-1 production and collagen fiber deposition.
Spred2‑deficiency increases the proliferation of bronchial epithelial cells in BLM‑treated 
 Spred2−/− mice. Previous studies demonstrated that both epithelial cells and fibroblasts contribute to the 
development of PF, and the results of genetic studies suggested that the dysfunction of epithelial cells play a role 
in the development of lung  fibrosis2. To elucidate a potential mechanism by which Spred2-deficiency allevi-
ates BLM-induced PF, we first focused on epithelial cells. One day after BLM instillation, similar numbers of 
apoptotic epithelial cells were detected in both WT and  Spred2−/− lungs as shown by TUNEL (Fig. 3). Similar 
numbers of  Ly6G+ neutrophils were detected mainly in the alveolar regions at this stage (Fig. 3). Small numbers 
of  BrdU+ cells were also detected in the bronchi of both WT and  Spred2−/− lungs (Fig. 3).
On day 7, a number of  BrdU+ cells were detected in the lung of WT mice. Most of them were located in the 
alveolar area and only a few  BrdU+ cells were detected among bronchial epithelial cells. By contrast, in the lung 
of  Spred2−/− mice, significantly larger numbers of  BrdU+ cells were detected among bronchial epithelial cells 
mainly of large bronchi with a small number of  BrdU+ cells of small bronchi and outside the bronchus (Fig. 4a). 
By double-staining, the majority of  BrdU+ cells were positive for keratin 5 but a few of them were positive for 
CC10. There was no  BrdU+ cells among acetylated tubulin-positive cells (Fig. 4b), indicating that they were basal 
cells and Clara cells.
To examine the ability of lung epithelial cells to proliferate, we isolated lung epithelial cells (LECs), including 
both bronchial and alveolar epithelial cells, from WT and  Spred2−/− lungs by negative selection of  CD45− cells, 
followed by positive selection of  CD326+ cells, and evaluated their ability to proliferate in vitro (Fig. 5a). The 
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proliferation of  Spred2−/− LECs was slightly but significantly higher than that of WT LECs. We also isolated 
tracheal epithelial cells (TECs) and evaluated their ability to proliferate. As shown in Fig. 5b, compared with 
WT TECs, a larger number of  Spred2−/− TECs could be found on the plastic surface of 96-well plates after 5 days 
of culture in DMEM. By CCK-8 assay, the proliferation of  Spred2−/− TECs was significantly higher than that 
of WT TECs in both DMEM containing 10% FBS and keratinocyte serum free medium (KSFM) containing 
epithelial growth factor (EGF). Addition of BLM to KSFM (EGF +) impaired the proliferation of both WT and 
 Spred2−/− TECs (Fig. 5c), indicating that the direct effect of BLM on the proliferation of WT and  Spred2−/− TECs 
was similar.
Since it was difficult to culture primary epithelial cells in vitro, we analyzed the role of Spred2 in the prolifera-
tion of lung epithelial cells by knocking down the expression of Spred2 by Spred2-specific siRNA in MLE-12 cells 
that present the distal bronchiolar and alveolar  epithelium21. Spred2-specific siRNA-treated cells proliferated 
significantly higher than cells transfected with control siRNA (Fig. 5d). These results supported the hypothesis 
that decreased PF detected in  Spred2−/− lung may be due to the increased proliferation of bronchial epithelial cells.
Reduced BML‑induced PF development in  Spred2−/− mice is not due to Spred2‑deficiency in 
myeloid cells. We previously demonstrated that the production of proinflammatory mediators was up-reg-
ulated in  Spred2−/− resident or M-CSF-induced BM-derived  macrophages22,23. Here, we examined the produc-
tion of TNFα and MCP-1 by inflammatory macrophages obtained by intraperitoneal injection of thioglycolate 
(TG) in response to BLM or LPS. BLM was previously reported to induce cytokine production in  macrophages24. 
Upon injury to lung epithelial cells, translocated bacteria and injured host cells could release ligands for toll-
Figure 1.  Characterization of lungs from naïve WT and  Spred2−/− mice. (a) Lung tissues were removed 
from WT and  Spred2−/− mice and examined by H&E staining. Bronchi are indicated by (B). The original 
magnification was 200×. The scale bars are 100 μm. (b) Naïve WT and  Spred2−/− mice were intraperitoneally 
injected with BrdU. Two hours later, mice were euthanized and the incorporation of BrdU was examined by 
IHC. The number of  BrdU+ cells in five bronchi were counted and presented as  BrdU+ cells/100 cells. The results 
are presented as mean ± SEM. n = 5. The original magnification was 400×. The scale bars are 50 μm. (c) The 
expression of the Cadh1, Fn1, Vim and Col1a1 gene was examined by qRT-PCR. The results are presented as 
mean ± SD. n = 4. *p < 0.05. ***p < 0.0001.
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Figure 2.  Characterization of lungs from naïve WT and  Spred2−/− mice after intratracheal instillation of BLM. 
Mice were injected intratracheally with 1.5 mg/kg BLM (equivalent to 1.5 U/kg). (a) Representative images 
of lung Sects. 7, 14 and 28 days after BLM administration are shown. H&E staining and Masson’s trichrome 
staining were performed. The original magnification was 200 × for Day 7 and 14, and 40 × for Day 28. The scale 
bars are 100 μm for Day 7 and 14, and 500 μm for Day 28. (b) The ratios of fibrosis area to total lung area were 
calculated as described in the M&M section. The results are presented as mean ± SD. n = 5 for WT and 8 for 
 Spred2−/− mice. (c) MCP-1 protein levels in the whole lung tissue 14 days after BLM injection were measured by 
ELISA. The results are presented as mean ± SD. n = 5 for WT and 8 for  Spred2−/− mice. *p < 0.05 and **p < 0.01. 
(d) The expression of the Fn1 and Vim gene in the lung 14 days after BLM injection was examined by qRT-PCR. 
The results are presented as mean ± SD. n = 5 for WT and 9 for  Spred2−/− mice. *p < 0.05 and **p < 0.01. (e) Mice 
were injected with 3 mg/kg (equivalent to 3 U/kg) BLT and the survival of mice was examined. n = 11 for WT 
and 9 for  Spred2−/− mice. *p < 0.05.
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like receptor 4 (TLR4), such as LPS and high mobility group box  1, and these TLR4 ligands could activate 
macrophages and induce the production of proinflammatory cytokines. As shown in Fig. 6a, WT and  Spred2−/− 
inflammatory macrophages produced similar levels of TNFα or MCP-1 in response to LPS after 24-h incubation. 
They also produced similar levels of TNFα or MCP-1 in response to BLM with similar kinetics.
To obtain additional evidence that Spred2-deficiency in myeloid cells, such as macrophages, is not responsible 
for the reduced PF development in response to BLM, we examined the development of PF in myeloid cell-specific 
Spred2-deficient mice  (LysMCre+Spred2F/F). We first generated Spred2-floxed mice  (Spred2F/F) by inserting two 
loxP sites flanking exon 6 of the Spred2 gene and then crossed them to LysMCre mice (Supplementary Fig. S2a). 
Deletion of exon 6 in the bone marrow cells of the conditional Spred2-deficient mice was confirmed by PCR 
(Supplementary Fig. S2b) As shown in Fig. 6b,c, similar levels of collagen deposition were present in the lung 
of both  LysMCre+Spred2F/F and control  LysMCre−Spred2F/F mice as indicated by Masson’s trichrome staining. 
These results indicate that the Spred2-deficiency in myeloid cells, such as macrophages, was not responsible for 
the reduced BLM-induced PF development in  Spred2−/− mice.
Increased proliferation of fibroblasts in the absence of Spred2 in vitro. We next examined fibro-
blasts. Lung fibroblasts were obtained from the lung of WT and  Spred2−/− mice and propagated in vitro. As 
shown in Fig. 7a, the phosphorylation of ERK was constitutively increased in  Spred2−/− fibroblasts. The level of 
αSMA tended also higher in  Spred2−/− fibroblasts but the difference was not statistically significant. The stimu-
lation with the TLR4 ligand LPS did not affect its level (Fig. 7b).  Spred2−/− fibroblasts proliferated significantly 
faster than WT fibroblasts without any additional stimuli by MTT assay (Fig. 7c). The production of MCP-1 in 
the absence or the presence of LPS was similar between WT and  Spred2−/− fibroblasts (Fig. 7d). Thus, Spred2-
deficiency in fibroblasts did not appear to account for the reduced BLM-induced PF development in  Spred2−/− 
mice.
Accumulation of Spred2 mRNA in bronchial epithelial cells of BLM‑treated WT mice. To 
obtain additional evidence supporting the hypothesis that Spred2-deficiency in bronchial epithelial cells was 
Figure 3.  Characterization of lungs from naïve WT and  Spred2−/− mice 1 day after BLM administration. Mice 
were injected intratracheally with 1.5 mg/kg BLM and lung tissues were harvested after 24 h. Tissue sections 
were subjected to H&E staining, TUNEL and IHC with anti-Ly6G Ab. To detect the proliferation of cells, BrdU 
was intraperitoneally injected 2 h before the harvest and the incorporation of BrdU was evaluated by IHC. 
Representative images are shown. The original magnification was 200 × for H&E staining and 400 × for TUNEL, 
Ly6G or BrdU staining. Arrows indicate positive cells. The number of  TUNEL+ or  BrdU+ cells in five bronchi 
were counted and presented as  TUNEL+ or  BrdU+ cells/100 cells.  Ly6G+ cells in five high power field (400×) 
were counted and the results are presented as mean ± SEM. n = 5. Scale bars are 100 μm for H&E and Ly6G 
staining and 50 μm for TUNEL and BrdU staining.
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responsible for the alleviated PF in  Spred2−/− mice, we examined the expression of Spred2 in the mouse lung. 
We attempted to detect Spred2 protein by IHC using several antibodies, but our attempts were not successful. 
Therefore, we used in situ hybridization (ISH) to detect Spred2 mRNA. As shown in Fig. 8a,b, significant levels 
of Spred2 mRNA (blue-green dots) could be detected in almost all bronchial epithelial cells, but not in alveolar 
epithelial cells, of untreated WT mice. The expression levels appeared to decrease on day 1 and day 7 after BLM 
administration. Interestingly, however, strong accumulation of Spred2 mRNA was observed in approximately 
50% of bronchial epithelial cells with a distinctive dome-shaped luminal surface, characteristic of Clara  cells25. 
Figure 4.  Increased proliferation of bronchial epithelial cells of  Spred2−/− mice 7 days after BLM administration. 
(a) Mice were injected intratracheally with 1.5 mg/kg BLM and lung tissues were harvested after 7 days. To 
detect the proliferation of cells, BrdU was intraperitoneally injected 2 h before the harvest. Tissue sections were 
subjected to H&E staining or IHC for BrdU. Representative images are shown. The original magnification was 
200 × for H&E staining and 400 × for BrdU staining. The number of  BrdU+ cells in five bronchi were counted 
and presented as  BrdU+ cells/100 cells. The results are presented as mean ± SEM. n = 5. *p < 0.05. Scale bars are 
100 μm for H&E staining and 50 μm for BrdU staining. (b) To determine cell types of  BrdU+ cells, consecutive 
tissue sections were subjected to H&E staining or IHC with antibodies against keratin 5, CC10 or acetylated 
tubulin. The original magnification was 400×. Arrow indicates the region where several  BrdU+ cells were found. 
Scale bars are 50 μm.
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These findings strongly support the role of Spred2 in the proliferation of bronchial epithelial cells and tissue 
repair in this model.
Discussion
BLM-induced cell toxicity occurs in various organs, such as the lung and skin, and mucous membranes, due 
to the lack of BLM hydrolase, the enzyme that inactivates BLM. Delivery of BLM to the lung causes pulmo-
nary injury, inflammation, and subsequent  fibrosis8. Spred2 is an endogenous inhibitor of the Ras/Raf/MEK/
ERK pathway involved in a variety of cellular processes, including cell proliferation and  inflammation26. We 
previously examined the role of Spred2 in lung injuries by using two acute injury models; LPS-induced ALI 
and ischemia–reperfusion injury  models19,20. In both studies, lung injury was exacerbated in the absence of 
Spred2 with increased inflammatory responses. These results led us to the hypothesis that Spred2-deficiency 
may enhance PF development induced by the administration of BLM. Contrary to our hypothesis, however, 
the development of PF was alleviated in  Spred2−/− mice compared to WT mice. This was associated with an 
Figure 5.  Increased proliferation of  Spred2−/− mouse bronchial epithelial cells in vitro. (a) Lung epithelial cells 
(LECs) were obtained from naïve WT and  Spred2−/− mice by negative selection with anti-CD45 Ab, followed 
by positive section with anti-CD326 Ab. Thirty thousand cells were seeded in 96-well plates and cultured for up 
to 4 days in DMEM containing 10% FBS. The growth of cells was evaluated by the CCK-8 assay. The results are 
presented as mean ± SEM. *p < 0.05, **p < 0.001. n = 4. (b) Tracheobronchial epithelial cells (TECs) were isolated 
from lungs of WT and  Spred2−/− mice as described in M&M. Five thousand cells were cultured in 96-well plastic 
plates in DMEM containing 10% FBS for 5 days and cells adhered to the plates were observed under inverted 
microscope. Representative images are presented. Scale bars are 50 μm. (c) Thirty thousand TECs were seeded 
in 96-well plates and cultured for up to 5 days in DMEM containing 10% FBS, KSFM plus EGF or KSFM 
plus EGF plus 20 μg/ml BLM. The growth of cells was evaluated by CCK-8 assay. The results are presented 
as mean ± SEM. *p < 0.05, **p < 0.001, ***p < 0.0001, ****p < 0.00001. n = 3. (d) MLE-12 mouse lung epithelial 
cell line cells were transfected with 10 pM Spred2-specific or control siRNA and the proliferation of cells was 
evaluated by CCK-8 assay. The results are presented as mean ± SEM. n = 12. ****p < 0.00001.
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increase in bronchial epithelial cell proliferation. Furthermore, the proliferation of  Spred2−/− LECs and TECs 
or MLE-12 cells transfected with Spred2-specific siRNA was higher than that of control cells in vitro. By ISH, 
Spred2 mRNA was detected almost exclusively in bronchial epithelial cells. These results strongly suggested that 
Spred2-deficiency alleviates BLM-induced PF via increased proliferation of bronchial epithelial cells that reduces 
subsequent development of PF by promoting the healing of injured lung tissues. To our knowledge, this is the 
first study to demonstrate a role of Spred2 in PF.
Figure 6.  A role of macrophages in the decreased BLM-induced PF in  Spred2−/− mice. (a) One million 
TG-induced peritoneal macrophages were cultured in 12-well plates in the presence of different doses of 
BLM for different time periods or 100 ng/ml LPS for 24 h. Production of TNFα and MCP-1 was evaluated 
by ELISA. The results are presented as mean ± SEM. n = 3. (b) The development of PF was evaluated by using 
 LysMCre+Spred2F/F mice and  LysMCre−Spred2F/F mice. Representative images of H&E (left) and Masson’s 
trichrome staining (right) are shown. The original magnification was 200×. The scale bar is 100 μm. (c) The 
ratios of fibrosis area to total lung area were calculated as described in the M&M section. The results are 
presented as mean ± SD. n = 5 for each group.
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The bronchial epithelium protects the internal milieu of the lung by forming a physical barrier involving 
adhesive complexes and a chemical barrier involving the secretion of mucus, and most environmental challenges 
are largely overcome without the need to develop inflammatory  responses27. The injury to bronchial epithelial 
cells is followed by an inflammatory phase characterized by the infiltration of leukocytes, increased vascular leak 
and upregulation of pro-inflammatory cytokines and chemokines. In LPS-induced ALI model, lung injury was 
exacerbated with increased inflammatory responses in  Spred2−/−  mice19. LPS injected into the trachea can directly 
activate TLR4 on bronchial epithelial cells and alveolar macrophages to produce proinflammatory cytokines and 
chemokines, whereas BLM damages epithelial cells and the induction of the inflammatory response is secondary 
to the damage to epithelial injury. Thus, the mechanisms of lung injuries caused by intratracheal injection of LPS 
or BLM are different, and this may explain the reason why the two models provided quite opposite outcomes.
During the development of PF, lung macrophages produce a variety of cytokines critical for the  process28. 
We found that the production of the proinflammatory cytokine TNFα and the chemokine MCP-1 in response 
to BLM or LPS by  Spred2−/− inflammatory macrophages was similar to that by WT macrophages, suggesting 
that Spred2-deficiency in macrophages is not responsible for the decreased level of PF in  Spred2−/− mice. When 
myeloid cell-specific Spred2-deficient mice were subjected to BLM, they developed similar levels of PF to that 
in control mice. Thus, Spred2-deficiency in myeloid cells does not account for the decreased PF detected in 
systemic  Spred2−/− mice.
Fibroblasts are another candidate cell population that contributes to the development of PF. Epithelial cell 
dysfunction or damages can lead to the activation of fibroblasts and the deposition and remodeling of matrix. 
The myofibroblast is the classic pathologic fibroblast phenotype described in IPF  lungs2,29. In the present study, 
lung fibroblasts isolated from  Spred2−/− mice showed an increased level of constitutive ERK phosphorylation 
Figure 7.  Increased proliferation of  Spred2−/− fibroblasts in vitro. Lung fibroblasts were obtained from WT 
and  Spred2−/− mice and cultured in vitro. (a) The phosphorylation of ERK was examined by western blotting. 
Representative photos of the blots are presented. The results of estern blotting were also quantitated by using the 
ImageJ software. The results are presented as mean ± SD. n = 3. (b) The expression of αSMA was examined by 
western blotting with or without LPS-stimulation. The results of western blotting were also quantitated by using 
the ImageJ software. The results are presented as mean ± SD. n = 2. (c) The proliferation of lung fibroblasts was 
examined by MTT assay. The results are presented as mean ± SEM. n = 12. (d) The production of MCP-1 by lung 
fibroblasts was examined by ELISA. The results are presented as mean ± SD. n = 3.
10
Vol:.(1234567890)
Scientific RepoRtS |        (2020) 10:16490  | https://doi.org/10.1038/s41598-020-73752-3
www.nature.com/scientificreports/
and proliferation compared to those from WT mice. They also produced a high level of MCP-1 with or without 
stimulation. Thus,  Spred2−/− fibroblasts appear to be more myofibroblast-like in the in vitro culture. On the other 
Figure 8.  Expression of Spred2 mRNA in the lung of WT mice before and after BLM treatment. Lungs were 
harvested from untreated WT mice (naïve) or 1, 7 or 14 days after the intratracheal instillation of BLM. (a) The 
expression of Spred2 mRNA was examined on day 0 (naïve), 1 and 7 after BLM treatment by ISH. Left panels: 
H&E staining. Middle panels: ISH. Right panels: The area indicated by a rectangle in the middle panel is further 
magnified. Almost all cells expressed a significant level of Spred2 mRNA (blue-green dots) in naive mice as 
indicated by arrows. By contrast, Spred2 mRNA was expressed at a low level on day 1 and 7 as indicated by an 
arrow. The magnification of the original photos was 400×. The scale bars are 50 μm. (b) The expression of Spred2 
mRNA on day 14 was examined by ISH. Top left panel: H&E staining. Bottom left panel: The area indicated by a 
rectangle in the top left panel is further magnified. Top right panel: ISH. Bottom right panel: The area indicated 
by a rectangle in the top right panel is further magnified. Spred2 mRNA accumulated in approximately 50% 
of bronchial epithelial cells, likely Clara cells by morphology, as indicated by arrows. The magnification of the 
original photos was 400×. The scale bars are 50 μm.
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hand, the degree of fibrosis was lower and the number of  BrdU+ fibroblasts were not increased in the lung of 
BLM-treated  Spred2−/− mice in vivo, showing a reverse behavior of  Spred2−/− fibroblasts in the in vitro culture 
and in the tissue. These observations strongly suggest that Spred2-deficiency in fibroblasts did not contribute to 
the alleviated PF in  Spred2−/− mice.
The phenotype of  Spred2−/− mice in BLM-induced PF model is similar to that detected in an acute colitis 
model induced by dextran sulfate sodium (DSS)30. In the colitis model, DSS damages colonic epithelial cells, 
resulting in the translocation of bacteria followed by activation of cells in mucosa and induction of inflammatory 
responses. Colonic epithelial cells of DSS-treated  Spred2−/− mice exhibited increased proliferation and healing 
compared to those of WT mice, likely resulting in decreased levels of acute colitis. These findings suggest interest-
ing dual roles of Spred2; the loss of Spred2 in epithelial cells is anti-inflammatory whereas the loss of Spred2 in 
leukocytes, such as macrophages, is proinflammatory. The role of Spred2 in neuro-regeneration was studied in 
the dorsal telencephalon followed by mechanical-lesion using zebrafish. Interestingly, the expression of Spred2 
was significantly reduced in the telencephalon post-lesion and gradually increased to normal levels, suggesting 
that a decrease in spred2 level after injury might be associated with activation of the ERK pathway to stimulate 
cell proliferation in the adult zebrafish  brain31. The expression of Spred2 mRNA also decreased in whole lungs of 
BLM-treated WT mice on day 7 and 14 by qRT-PCR (Supplementary Fig. S3). A similar decrease was observed 
in bronchial epithelial cells on day 1 and 7 by ISH, but strong accumulation of Spred2 mRNA was detected in a 
portion of epithelial cells, likely Clara cells. These findings suggest that the expression of Spred2 may be altered 
during the host response to a damage to bronchial epithelial cells. The role of Spred2 in cell proliferation was 
also found in other mouse disease  models32,33. In the meantime, it remains unclear why increased  BrdU+ cell 
population in BLM-treated  Spred2−/− mice was basal cells of large bronchi, but not of Clara cells. Additional 
studies using conditional  Spred2−/ mice in which Spred2 is deficient in basal cells or Clara cells will be important 
to better understand the role of Spred2 in the proliferation of these cell types. It is also important to validate 
the data obtained by ISH at a protein level when a reliable antibody against mouse Spred2 becomes available.
We recently obtained human lung tissues from lung cancer patients with significant PF in the background, 
and isolated fibroblasts from non-fibrotic and fibrotic lesions of each case. Our preliminary results obtained 
by qRT-PCR suggest that the expression of Spred2 mRNA by fibroblasts from the fibrotic lesions of UIP cases 
was significantly increased (data not shown). It is unclear what this means at present, but it is possible that the 
expression of Spred2 mRNA is dysregulated in those cells. Unlike in the mouse model, PF in the patients was 
more advanced and we cannot compare the results obtained from the mouse model and human patients. More 
detailed studies, including the expression of Spred2 in epithelial cells, are necessary to understand the role of 
Spred2 in the development of human PF.
In conclusion, we have identified a novel role of Spred2 in the development of PF after injury by BLM in 
mice. Unlike previous reports demonstrating that endogenously expressed Spred2 negatively regulates acute 
inflammatory responses by downregulating the production of proinflammatory cytokines, downregulation of 
Spred2 may be beneficial for the recovery of the epithelium. Thus, this possibility should be considered when 
Spred2-mediated therapy is proposed to treat patients with PF and other inflammatory diseases.
Materials and methods
Reagents. Fetal bovine serum (FBS) was from HyClone (Logan, UT). KSFM was from Gibco (Grand Island, 
NY). Antibodies against p44/42 MAPK (ERK1/2), phospho-p44/42 MAPK (ERK1/2) and GAPDH were from 
Cell Signaling Technology (Danvers, MA). DMEM, LPS (011B4) and BrdU were from Sigma-Aldrich, St. Louis, 
MO. Rat monoclonal Ab against Ly6G (clone 1A8) and rabbit polyclonal Ab against keratin 5 were from BioLe-
gend (San Diego, CA). Rabbit polyclonal antibodies against αSMA or CC10 were from Proteintech (Rosemont, 
IL). Mouse monoclonal Ab against acetylated tubulin (clone 6-11B-1) was from Sigma Aldrich. Rat monoclonal 
Ab against BrdU (clone ICR1) was from GeneTex (Irvine, CA). BLM (BLM-AP302) was from Enzo Life sci-
ence (Farmingdale, NY). PCR primers for Spred2 (Mm 01223872_g1) (Hs 00986220_m1), Fn1 (Mm 01256744_
m1) (Hs 00365052_m1), Vim (Mm 01333430_m1) (Hs 00185584_m1), Cdh1 (Mm01247357_m1), Col1a1 
(Mm00801666_g1), TNFα (Mm00443258_m1), TGF-β1 (Mm 01178820_m1), Mcp-1/Ccl2 (Mm 00441242_m1) 
were from Applied Biosystems (Foster City, CA).
Mice. The generation of Spred-2−/− mice on the C57BL/6J background was previously  reported15. C57BL/6J 
mice were used as WT mice. The absence of Spred2 mRNA expression in the lung of  Spred2−/− mice was con-
firmed by RT-qPCR.
To generate  Spred2F/F mice, an approximately 11-kb fragment of mouse genomic DNA spanning the exon 5 
and 6 of the Spred2 gene was retrieved from a mouse BAC clone into pLMJ235 vector containing the thymidine 
kinase gene. A loxP site and a neo cassette flanked by two loxP sites were inserted downstream and upstream of 
exon 6 by using a recombinogenic cloning method. The targeting vector was then electroporated into C57BL/6 
mouse ES cells and Spred2 flox-neo mice were generated. To generate Spred2 floxed mice  (Spred2F/F), Spred2 
flox-neo mice were crossed to CAG-Flpe mice on a C57BL/6  background34 (RIKEN Bioresource Center, Tsukuba, 
Japan). Heterozygous mice  (Spred2F/+) were mated to generate homozygous Spred2 floxed mice  (Spred2F/F) 
(Supplementary Fig. S2a).  Spred2F/F mice were then crossed to LysMCre on a C57BL/6 genetic  background35 to 
generate myeloid cell- specific  Spred2−/− mice (Supplementary Fig. S2b).
All mice were bred and maintained under a continuous 12 h light: 12 h dark cycle in a specific pathogen-free 
condition at the Department of Animal Resources, Okayama University (Okayama, Japan). Male mice (8-week-
old) were used in this study. Mice were fed a standard laboratory diet and water ad libitum. The Animal Care and 
Use Committee at Okayama University approved all animal experiments conducted in this study (OKU-2013348, 
OKU-2018064), and all experiments were performed in accordance with relevant guidelines and regulations.
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Bleomycin‑induced pulmonary fibrosis model. Mice were anesthetized with intraperitoneal injection 
of sodium pentobarbital, followed by ketamine HCl, and intratracheally injected with BLM dissolved in PBS 
(1.5 mg/kg). At 1, 7 and 14 days after BLM administration, mice were euthanized. The left lobe of the lung was 
fixed with neutral buffered formalin and embedded in paraffin; 4-µm paraffin sections were made and stained 
with H&E or Masson’s trichrome staining. The tissue was outlined by the freehand selection tool and fibrotic 
area was measured by using the ImageJ 1.45. according to the method by A. Onoda (https ://www.slide share .net/
mobil e/atsut oonod a/image -j-52335 489). The right lobe was immediately frozen in liquid nitrogen and used for 
RT-qPCR and ELISA. To examine cell proliferation in vivo, mice were intraperitoneally injected with BrdU. Two 
hours later, mice were euthanized and the incorporation of BrdU was examined by IHC.
Isolation of lung epithelial cells (LECs). Mouse LECs were isolated from non-treated mice using a pre-
viously described method with  modifications36. In brief, lungs were removed from untreated WT or  Spred2−/− 
mice. They were minced in a gentleMACSTM Dissociator (Miltenyi Biotec, Gladbach, Germany) and digested 
in 5 ml Hank’s balanced salt solution (HBSS) containing 20 μg/ml collagenase (Wako, Japan), 150 U/ml DNase 
I (Roche, Basel, Switzerland) and 20 mM HEPES (Gibco), for 30 min at 37 °C with occasional shaking. The 
cell suspensions were filtered through 100-μm nylon mesh, and centrifuged at 400 × g for 6 min. The cells were 
washed once with PBS and then incubated with anti-CD45 microbeads.  CD45+ cells were removed over MS 
MiniMACS separation columns (Miltenyi Biotec), and  CD45− cells were collected and incubated with biotin-
labeled anti-CD326 Ab (Biolegend, USA), followed by addition of streptavidin-coated microbeads. Magnetic 
beads-labeled  CD326+ cells were collected on a separation column, suspended in DMEM high glucose medium 
containing 10% FBS.  CD326+ cells included bronchial and alveolar epithelial cells.
Isolation of tracheobronchial epithelial cells (TECs). Tracheobronchial epithelial cells (TECs) were 
isolated using a previously described method with  modifications37,38. Briefly, tracheal tissues from 6 WT or 
Spred2 KO mice were placed into a 50  ml conical tube containing 30  ml DMEM containing penicillin and 
streptomycin on ice. In a sterile lamellar flow hood, tracheal tissues were transferred to a sterile 100 mm petri 
dish containing 10 ml DMEM with antibiotics. Connective tissues were gently dissected with sterile forceps 
and surgical scissors. Tracheal tissues were transferred to a new 100 mm petri dish containing 10 ml DMEM 
containing antibiotics to rinse. Tracheas were cut along vertical axis to expose lumen, and then transferred to 
a 50 ml tube containing 10 ml DMEM with 0.15% pronase and antibiotics (pronase solution). After overnight 
incubation at 4 °C, the tubes were gently rocked 10–12 times, and then let stand for 30–60 min at 4 °C. Ten ml 
DMEM containing 20% FBS and antibiotics was added to each tube and the tubes were rocked 12 times. Tra-
cheas were removed from pronase solution, and this solution was set aside on ice. Tracheas were transferred to a 
conical tube containing DMEM and the tubes were inverted 12 times. This process was repeated two more times. 
Pronase solution was combined with the three supernatants from the previous step into one 50 ml tube, and the 
remaining tissues were discarded. The 50 ml tubes were centrifuge at 1400 rpm (390 × g) for 10 min at 4 °C, and 
the supernatants were discarded. The cell pellets were gently resuspended in 1 ml DNase I solution (100–200 μl/
trachea), incubated for 5 min on ice and centrifuged at 1400 rpm (390 × g) for 5 min at 4 °C. The cell pellet was 
resuspended in 8 ml DMEM containing 10% FBS, plated on petri dish, incubated at 37 °C in a  CO2 incubator 
for 5 h (Note: this is a negative selection step for fibroblasts), and then nonadherent cells (cell suspension) were 
collected from the dishes. The dishes were rinse twice with 4 ml DMEM containing 10% FBS. Cell suspension 
and washes were pooled together in a 50 ml conical tube, centrifuged and resuspended in DMEM containing 
10% FBS. The concentration of cells was examined by trypan blue staining.
Isolation of lung fibroblasts. Lung fibroblasts were isolated from non-treated mice, as previous 
 described39. In brief, lung tissues were isolated under sterile condition, and 1 mm3 fragments were placed on 
tissue culture plates containing high glucose DMEM with 15% FBS and then incubated at 37 °C in a 15%  CO2 
atmosphere. After 5-day culture, lung tissues were removed from the plates and fibroblasts were grown to 80% 
confluence, and then transferred to 175 mm2 flasks. Fibroblasts were then harvested and used for RT-qPCR, 
MTT assay and western blotting.
Short‑interfering (si) RNA. One million MLE-12 cells (ATCC, Manassas, VA) were transfected with 
2 μg Spred2-specific or control siRNA (Thermo Scientific, Yokohama, Japan) using the Amaxa nucleofector kit 
V (Lonza Cologne AG, Cologne, Germany) according to the manufacturer’s instructions, and plated in a 24-well 
plate. The siRNA efficacy was validated by real-time qRT-qPCR. The expression of Spred2 was routinely 30% or 
less of the levels detected in control cells.
Real‑time quantitative PCR (RT‑qPCR). Total RNA was isolated from cultured cells or whole lungs 
using the High Pure RNA Isolation Kit or High Pure RNA Tissue Kit (Roche Applied Science, Mannheim, 
Germany), respectively. First-strand cDNAs were synthesized from total RNA using the High capacity cDNA 
reverse transcription kit (Applied Biosystems, Foster City, CA, USA), and used as templates for PCR. RT-qPCR 
analysis was performed using the StepOnePLus Real-Time PCR system with Taqman PCR master mix (Applied 
Biosystems). The level of gene expression was normalized using the level of GAPDH expression as an internal 
control, and relative fold change values were calculated based on unstimulated or WT control group that were 
assigned an arbitrary value of 1.
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ELISA. The concentrations of murine cytokines were measured using a standard sandwich ELISA method, 
as previously  described40. ELISAs used in this study did not cross-react with other known murine cytokines. 
For lung cytokine measurements, lungs were homogenized in PBS containing 0.1% TritonX-100 and complete 
protease inhibitor (Roche) and centrifuged; the cleared supernatants were harvested and used for ELISAs.
Western blotting. Cells or lung tissues were lysed in a lysis buffer (Cell Signaling), briefly sonicated, incu-
bated on ice for 30 min, and then centrifuged at 12,000×g for 10 min. Supernatants were collected and stored 
at – 30 °C until use. For protein fractionation, 10 µg of each cell lysate was loaded on gels and proteins were 
fractionated by sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis (Life Technologies) and trans-
ferred onto nitrocellulose membranes. After overnight incubation with a primary antibody, the membranes were 
washed and incubated with horseradish peroxidase-conjugated anti-rabbit or -mouse IgG secondary antibody 
(Santa Cruz Biotechnology, Santa Cruz, CA, USA). The presence of proteins of interest was visualized and quan-
titated with C-DiGit Blot scanner (Scrum, Tokyo, Japan). Blots were photographed, digitized and the density of 
each band was analyzed using Image J, a public domain software developed by the NIH.
Detection of apoptotic cells. Apoptotic cells in the lung were detected by TUNEL assay using the in situ 
apoptosis detection kit (TACS2 TdT-DAB; Trevigen, Gaithersburg, MD) according to the manufacturer’s 
instructions except that hematoxylin was used for counterstaining. The number of positive cells was counted 
under microscope.
Immunohistochemistry (IHC). Serial sections of 4-μm thickness were prepared from formalin-fixed and 
paraffin-embedded blocks. One section was stained with H&E and others were used for immunohistochemistry 
for each block. Immunostaining was performed manually by a conventional method as previously  reported41. 
Briefly, sections were deparaffinized in xylene and rehydrated in a sequence of descending concentrations of 
ethanol. Endogenous peroxidase reactivity was blocked with 3%  H2O2 for 10 min. Sections were enclosed in 
a pressure cooker with citrate buffer (pH6.0) and microwaved (500 W) continuously for 20 min for antigen 
retrieval, and then incubated with anti-BrdU (1:50) or anti-Ly6G (1:100) antibody for 1.5 h at room tempera-
ture. After washing, they were treated with peroxidase-labeled anti-rat IgG according to the manufacturer’s 
instructions. Histochemical reactions were developed using 3, 3-diaminobenzidine (DAB) as the chromogenic 
substrate for peroxidase. Finally, sections were counterstained with hematoxylin, dehydrated, and mounted. 
For double immunostaining, after antigen retrieval, sections were first treated with antibodies against keratin 5 
(1:500), CC10 (1:500) or acetylated tubulin (1:200), followed by alkaline phosphatase-labeled secondary anti-
bodies and histochemical reactions were developed using Vector Red. The additional immunohistochemistry for 
BrdU was started by antigen retrieval, followed by primary and secondary antibody incubation, and completed 
with histochemistry using DAB as a chromogen.
In situ hybridization (ISH). Expression of mouse Spred2 mRNA in lung tissues was detected by RNAScope 
2.5 Duplex Detection Kit (ACD, Inc., Hayward, CA) according to the direction provided by the supplier. Briefly, 
tissue sections in 5-μm thickness were deparaffinized in xylene, followed by rehydration in a sequence of 
descending concentrations of ethanol. Tissue sections were then incubated in Target Retrieval Reagent main-
tained at a boiling temperature (98 °C) using a hot plate for 20 min, rinsed in deionized water, dried and then 
treated with protease at 40 °C for 40 min in a Dako StatSpin Hybridizer (Agilent, Santa Clara, CA). Tissue sec-
tions were then incubated at 40 °C in a hybridization buffer containing target probes (Mm-Spred2-C1, # 527581-
C1) for 3 h. After the hybridization step, slides were washed with wash buffer three times at room temperature, 
and then multiple signal amplification molecules were hybridized. Chromogenic detection was performed using 
FastGreen, followed by counterstaining with  hematoxylin42. Images were acquired using an Olympus BX43 light 
microscope connected to a DP73 digital camera (Olympus, Tokyo, Japan).
Cell proliferation assay. Thirty thousand LECs in DMEM containing 10% FBS or TECs in DMEM con-
taining 10% FBS, KSFM containing EGF (5 ng/ml) or KSFM containing EGF plus BLM or MLE-12 cells in 
DMEM containing 10% FBS were seeded in 96-well plate and cultured for up to 5 days. The growth of cells was 
evaluated by the CCK-8 assay (Dojindo, Kumamoto, Japan). For fibroblasts, 5 × 103 cells in DMEM containing 
10% FBS were cultured in 96 well plates for 4 days and the proliferation of cells was evaluated by MTT assay 
(Sigma-Aldrich).
Statistics. Data were analyzed and plotted by using the GraphPad Prism 6.0e (GraphPad Software, San 
Diego, CA). The statistical significance of differences between data sets was evaluated using the Student’s t-test. 
p < 0.05 was considered to represent a statistically significant difference.
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